Enhancement of Chromosomal Damage by Arsenic: Implications for Mechanism

by Janice W. Yager and John K. Wiencke

Arsenic is a naturally occurring metalloid that has been associated with increased incidence of human cancer in certain highly exposed populations. Arsenic is released to the environment by natural means such as solubilization from geologic formations into water supplies. It is also released to occupational and community environments by such activities as nonferrous ore smelting and combustion of fuels containing arsenic. Several lines of evidence indicate that arsenic acts indirectly with other agents to ultimately enhance specific genotoxic effects that may lead to carcinogenesis. Work described here indicates that arsenite specifically potentiates chromosomal aberrations induced by a DNA crosslinking agent, 1,3-butadiene diepoxide, but does not affect the induction of sister chromatid exchanges under the same treatment conditions. It is proposed that the specific co-clastogenic effects of arsenite seen here may be mediated by its interference with DNA repair activities. Further understanding of the mechanism by which arsenic interacts with other environmental agents will result in more accurate estimates of risk from exposure to arsenic.

Background

Arsenic is naturally occurring in various geological formations and is released to the environment by solubilization into groundwater supplies (1). Release can also occur into community and occupational environments by such activities as nonferrous ore smelting and production of electric power by burning coal containing arsenic. When such coal is combusted, minute quantities of arsenic are emitted to the atmosphere depending on the arsenic content of the fuel. Arsenic content in U.S. bituminous coal may vary from about 0.02 μg/g up to 360 μg/g (2). Health risk estimates for current coal-fired utility arsenic emission levels have been derived using the inhalation unit risk estimates developed by the U.S. Environmental Protection Agency (EPA) (3). “Maximum individual lifetime” risk for cancer from arsenic from a modeled coal-fired power plant is estimated by EPA to be $1 \times 10^{-5}$.

Arsenic exists principally in two valence states: As$^{3+}$ (arsenite) or As$^{5+}$ (arsenate). Arsenite is considerably more acutely toxic than is arsenate, but the relationship of valence state to the potential induction of carcinogenesis is unknown. Arsenic also exists in organic forms and is often found in relatively high amounts in this form in fish as arsenobetaine.

Arsenic is a well-known toxin and is considered a human carcinogen based on epidemiological evidence (4,5). Studies of occupational exposure to high air concentrations of arsenic in copper smelters (6-11) and community exposure to significant arsenic levels in drinking water (12) have indicated an increased risk of lung and skin cancer, respectively. Follow-up studies of exposure to arsenic via drinking water in Taiwan have implied that increases in cancer at other internal sites such as bladder and kidney may have occurred as well (13-15). Populations studied in both occupational and community settings were simultaneously exposed to complex mixtures of other compounds and trace elements; there is also some evidence that nutritional and lifestyle factors such as smoking may have interacted with arsenic to produce a synergistic response (16,17).

In animal studies, arsenical compounds alone have not yielded a directly tumorigenic response (5). However, a mixture of arsenic trioxide, sulfuric acid, and particulates did induce pulmonary carcinomas in hamsters when administered by intratracheal instillation (18). Results of animal studies provide support for the rationale that arsenic acts in concert with other agents to alter or enhance biological effects potentially including steps in progression to carcinogenesis (19).

A number of hypotheses have been described concerning the possible mechanism of action of arsenic in cancer. Unlike most initiating chemicals, arsenic is inactive or extremely weak in its ability to directly induce gene mutations; however, it does cause gene amplification and may act as a tumor promoter (20,21). It has been suggested that arsenical compounds may interact antagonistically or syn-

1Electric Power Research Institute, Palo Alto, CA 94303.
2University of California, San Francisco, CA 94143.
Address reprint requests to J. W. Yager, Electric Power Research Institute, 3412 Hillview Ave., Palo Alto, CA 94303.
ergistically with other genotoxic exposures in humans (22). Epidemiological studies have indicated a synergistic interaction between arsenic exposure and cigarette smoking in smelter workers in the induction of lung cancer (17,23) and in the production of chromosomal aberrations in smelter workers (24). Arsenite has been shown to enhance the mutagenicity of UV treatment in bacterial cells (25) and to inhibit DNA ligase activity in mammalian cells (26). The induction of chromosomal aberrations in human cells by DNA crosslinking agents combined with UV light was observed to be synergistically enhanced by arsenite (27–29).

To further explore the possible potentiation of genotoxic damage by arsenite, experiments were undertaken to examine effects of arsenite exposure on the induction of chromosomal aberrations and sister chromatid exchanges by the DNA crosslinking agent 1,3-butadiene diepoxide [DEB (30)].

**Specificity of Arsenite in Enhancing Chromosomal Effects**

**Methods**

Peripheral lymphocytes from three subjects were cultured in RPMI 1640 tissue culture medium with supplements. Subject 1 was DEB-sensitive to sister chromatid exchange (SCE) induction, whereas subjects 2 and 3 were resistant to such induction as previously described (31,32). At 24 hr of culture, lymphocytes were treated with 0.5, 1.0, 1.5, and 2.0 μM sodium arsenite or 6 μM DEB. In a third series of experiments, DEB and arsenite were combined to treat cultured cells. In this protocol, DEB was added first, followed immediately by arsenite. Immediately after treatment, 50 μM bromodeoxyuridine was added. Cells were cultured for 72 hr at 37.5°C and treated with colcemid 2 hr before harvest. Standard chromosome preparations were differentially stained using a modification of the fluorescence-plus-Giemsa technique (33). For each subject, 100 first-division cells were scored per treatment for aberration frequencies. Aberrations scored were chromosome-type aberrations and chromatid and isochromatid deletions and chromatid exchanges. To estimate SCE frequencies, 30 second-division cells were scored per point; replication indexes were determined. Linear regression was applied to ascertain trends in aberration rates or SCE frequencies. Pairwise differences between observed and expected frequencies of chromosomal aberrations were assessed by the chi-square test; the student’s t-test was used to test for differences in mean SCE frequencies. Bonferroni’s method to correct for multiple comparisons was used to adjust the α level for significance (p < 0.05).

**Results and Discussion**

The yields of total chromosomal aberrations in lymphocytes exposed to both arsenite and DEB together were markedly increased above the levels expected if effects of the two agents had been simply additive (Fig. 1). For the DEB-sensitive subject (Fig. 1a), more than 300 chromosome aberrations were induced per 100 cells with the combined treatment at 2 μM sodium arsenite—an approximately 10-fold increase above expected.

As seen in Figure 1b, results of the combined treatment for subject 2, whose cells were relatively resistant to SCE induction by DEB, showed similar results. In this instance, however, about a 5-fold increase in the number of chromosome aberrations was observed relative to the number expected. Cells from subject 3 showed similar results.

In contrast, as shown in Figure 2, the yields of induced SCEs are additive for the combined DEB plus arsenite treatments, thus the expected and observed frequencies of SCEs are not significantly different. There were no sub-

![Figure 1](image-url)
strial differences among the three subjects with regard to this response.

These results show that arsenite acts synergistically with DEB in the induction of chromosomal aberrations but does not affect the yield of DEB-induced SCEs. Interestingly, neither the DEB-sensitive nor DEB-resistant subjects showed a synergistic effect with arsenite in the induction of DEB-induced SCEs. In contrast, the interaction of arsenite with DEB in the induction of chromosomal aberrations was found to be greatest in lymphocytes from the subject sensitive to SCE induction by DEB.

Although it has been recognized that arsenite reacts with protein sulfhydryl groups, it has now been shown that arsenite may be highly selective in reacting with only a small number of closely spaced dithiol groups in proteins (34, 35). Such dithiol groups are relatively common in DNA-associated protein molecules including DNA repair proteins (36). Specifically, the activity of DNA ligase, a mammalian DNA repair protein, has been shown to be inhibited by arsenite (26).

**Conclusion**

Arsenic is a ubiquitous metalloid known to be associated at relatively high exposure concentrations with an increased risk for certain cancers in humans. Arsenic does not appear to act directly as an initiator, but rather indirectly by as yet unknown mechanism(s) to enhance the effect of other genotoxic agents. Understanding of such mechanisms has implications for the shape of the dose-response curve. Recent studies, including the study summarized here, provide further evidence for arsenite as a co-clastogen. This study also suggests a specific interaction of arsenite with the induction or repair of DNA damage produced by DEB that leads to chromosomal aberrations but not to SCEs. Further studies are necessary to identify DNA repair proteins containing dithiol groups sensitive to low concentrations of arsenic. This work and other studies previously discussed support the proposal that arsenic exposure in combination with other DNA damaging agents leads to a specific enhancement of effects related to genotoxicity that may be important in development of cancer.

This work was supported in part by the office of Health and Environmental Research, U.S. Department of Energy, contract no. DE AC03 76 SF01012, and grant no. P42ES04705 from the National Institute of Environmental Health Sciences. The views expressed here are those of the authors and not those of the Electric Power Research Institute.

**REFERENCES**

1. Tanaka, T. Arsenic in the natural environment. Arsenic concentrations in thermal waters from Japan. Appl. Organometallic Chem. 4: 197–203 (1990).
2. U.S. EPA. Summary of Trace Emissions from and Recommendations of Risk Assessment Methodologies for Coal and Oil Combustion Sources. U.S. EPA Document No. 85-203-024-41-07, Environmental Protection Agency, Washington, DC, 1986.
3. U.S. EPA. Health Assessment Document for Inorganic Arsenic. Final Report. EPA - 600/R-85-021F, Environmental Protection Agency, Washington, DC, 1984.
4. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 23. Some Metals and Metallic Compounds. International Agency for Research on Cancer, Lyon, 1980, pp. 39–141.
5. IARC. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Supplement 7. Overview of Carcinogenicity: Updating of IARC Monographs Volumes 1–42. International Agency for Research on Cancer, Lyon, 1987, pp. 100–106.
6. Pinto, S. S., and Bennett, B. M. Effect of arsenic trioxide exposure on mortality. Arch. Environ. Health. 7: 583–591 (1963).
7. Lee, A. M., and Fraumeni, J. F. Arsenic and respiratory cancer in man: an occupational study. J. Natl. Cancer Inst. 42: 1045–1052 (1969).
8. Axelson, O., Dahlgren, E., Jansson, C. D., and Rehnlund, S. O. Arsenic exposure and mortality: a case–referent study from a Swedish copper smelter. Br. J. Ind. Med. 35: 8–15 (1978).
9. Enterline, P. E., and Marsh, G. M. Mortality studies of smelter workers. Am. J. Ind. Med. 1: 251–259 (1980).
10. Enterline, P. E., and Marsh, G. M. Cancer among workers exposed to arsenic and other substances in a copper smelter. Am. J. Epidemiol. 116: 895–911 (1982).
11. Welch, K., Higgins, L., Oh, M., and Burchfield, C. Arsenic exposure, smoking, and respiratory cancer in copper smelter workers. Arch. Environ. Health 57: 325–335 (1982).
12. Tseng, W. P., Chu, H. M., and Hu, Y. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 40: 453–63 (1968).
13. Chen, C. J., Chuang, Y. C., Lin, T. M., and Wu, H. Y. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high arsenic artesian well water and cancers. Cancer Res. 45: 5895–5899 (1985).
14. Chen, C. J., Chuang, Y. C., You, S. L., Lin, T. M., and Wu, H. Y. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br. J. Cancers 3: 399–405 (1986).
15. Chen, C. J., and Wang, C. J. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res. 50: 5470–5474 (1990).
16. Vahter, M., and Marafante, E. Effects of low dietary intake of methionine, choline or proteins on the biotransformation of arsenite in the rabbit. Toxicol. Lett. 37: 41–46 (1987).
27. Lee, T. C., Alexeef, D., Lipsett, M., and Nordberg, G. Synergism between occupational arsenic exposure and smoking in the induction of lung cancer. In press.
28. Lee, T. C., Lee, K. C., Tzeng, Y., Huang, R. Y., and Jan, K. Y. Sodium arsenite potentiates the clastogenicity and mutagenicity of DNA crosslinking agents. Environ. Mutagen. 9: 119–128 (1986).
29. Lee, T. C., Tzeng, S. F., Chang, W. J., Lin, Y. C., and Jan, K. Y. Post-treatments with sodium arsenite during G2 enhance the frequency of chromosomal aberrations induced by S-dependent clastogens. Mutat. Res. 163: 263–269 (1986).
30. Wiencke, J. K., and Yager, J. W. Specificity of arsenic in potentiating cytogenetic damage induced by the DNA crosslinking agent diepoxbytane. Environ. Mol. Mutagen. 19: 195–200 (1992).
31. Kelsey, K. T., Christiani, D. C., and Wiencke, J. K. Bimodal distribution of sensitivity to SCE induction by diepoxbytane in human lymphocytes: II. Relationship to baseline SCE frequency. Mutat. Res. 248: 27–33 (1991).
32. Wiencke, J. K., Wrensch, M. R., Miike, K., and Petrakis, N. L. Individual susceptibility to induced chromosomal damage and its implication for detecting genotoxic exposures in human populations. Cancer Res. 51: 5266–5269 (1991).
33. Perry, P., and Wolff, S. New Giemsa method for the differential staining of sister chromatids. Nature 251:156–158 (1974).
34. Joshi, S., and Hughes, J. B. Inhibition of coupling factor B activity by cadmium ion, arsenite-2,3-dimercaptopropanol, and phenylarsine oxide, and preferential reaction by dithiols. J. Biol. Chem. 266: 11112–11116 (1981).
35. Knowles, F. C., and Benson, A. A. The biochemistry of arsenic. Trends Biomed. Sci. 8: 178 (1983).
36. Berg, J. Zinc finger domains: hypothesis and current knowledge. Annu. Rev. Biophys. Chem. 19: 405–421 (1990).